Premium
Weekly rituximab consolidation following four cycles of R‐ CHOP induction chemotherapy in very elderly patients with diffuse large B‐cell lymphoma: Consortium for improving survival of lymphoma study ( CISL )
Author(s) -
Jung SungHoon,
Lee JeJung,
Kim Won Seog,
Lee WonSik,
Do Young Rok,
Oh Sung Yong,
Kim Min Kyoung,
Mun YeungChul,
Shin HoJin,
Kwak JaeYong,
Kang Hye Jin,
Won Jong Ho,
Kwon Jung Hye,
Park Eunkyung,
Suh Cheolwon,
Yang DeokHwan
Publication year - 2015
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12459
Subject(s) - rituximab , medicine , tolerability , lymphoma , chop , diffuse large b cell lymphoma , gastroenterology , chemotherapy , surgery , adverse effect
This study aimed to determine the objective response, toxicity, and clinical outcome of weekly rituximab consolidation after four cycles of R‐ CHOP 21 in very elderly patients with DLBCL . A prospective, multi‐institutional phase II trial was conducted on patients with previously untreated CD 20 + DLBCL who were older than 70 yr. Patients were treated with four cycles of R‐ CHOP 21 followed by weekly consolidation with rituximab (375mg/m 2 , four times infusion) ( NCT 01181999). We also compared the clinical outcomes with an historical case‐matched control group treated conventionally with six cycles of R‐ CHOP 21. A total of 51 patients with newly diagnosed DLBCL were enrolled at 15 institutes between June 2010 and September 2013 . The median age was 76 yr (range: 70–89). Forty‐one of the 51 patients completed the planned rituximab consolidation (R‐consolidation). The overall response rate was 78.4%, comprising 74.5% with a complete response and 3.9% with a partial response. After a median follow‐up of 20.3 months, 2‐yr progression‐free survival and overall survival were 63.9% and 68.7%, respectively. No serious toxicities were reported during rituximab consolidation. Weekly rituximab consolidation following four cycles of R‐ CHOP 21 resulted in an acceptable response with high tolerability and could be a good compromise between efficacy and safety for elderly patients with DLBCL .